Results 1 to 10 of about 400,118 (290)

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]

Haematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, Fabrizio Stracci, Richard F. Schlenk, Sergio Amadori, Christian Thiede, Susanne Schnittger, Peter J.M. Valk, Konstanze Döhner, Massimo F. Martelli, Markus Schaich, Jürgen Krauter, Arnold Ganser, Maria P. Martelli, Niccolò Bolli, Bob Löwenberg, Torsten Haferlach, Gerhard Ehninger, Franco Mandelli, Hartmut Döhner, Franziska Michor, Brunangelo Falini   +22 more
doaj   +5 more sources

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

Frontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado, Paulina González Galván, Israel Parra Ortega, Félix Gaytán Morales, Félix Gaytán Morales, Luis Juárez Villegas, Elisa Dorantes Acosta, Elisa Dorantes Acosta   +7 more
doaj   +1 more source

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

HemaSphere, 2021
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation ...
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora   +12 more
doaj   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

eJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund, Josefine Redig, Björn Paulsson, Åsa Rangert Derolf, Martin Höglund, Simona Vertuani, Gunnar Juliusson   +6 more
doaj   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

Einstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman, Fabio Pires de Souza Santos, Belinda Simões, Elias Hallack Atta, Fernando Callera, Jane de Almeida Dobbin, Éderson Roberto Mattos, Angelo Atalla, Angelo Maiolino, Maria Aparecida Zanichelli, Cristiane Fração Diefenbach, Marcia Torresan Delamain, Nelson Hamerschlak   +12 more
doaj   +3 more sources

CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]

, 2008
The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi, Akashi, Bai, Bottazzi, Bruserud, Cheng, Christensen, Conkright, Crans-Vargas, Deepa B. Shankar, Dejah R. Judelson, Desdouets, Deshpande, Elliot M. Landaw, Fried, Fu, Hestdal, Impey, Ingrid Schmid, Jamieson, Jenny Chang, Jerry C. Cheng, Kathleen M. Sakamoto, Kentaro Kinjo, Kim, Kinjo, Kohn, Kondo, Koschmieder, Koya, Krishan, Kwon, Lee, Mayr, Mendoza, Miyoshi, Montminy, Ninomiya, Noriyuki Kasahara, Passegué, Ravi Bhatia, Rehemtulla, Renata Stripecke, Scherr, Shah, Shankar, Shankar, Shaywitz, Stripecke, Traver, Tuschl, Van Etten, Ventura, Winston S. Wu, Wong, Yuan   +55 more
core   +3 more sources

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Biomarkers of leukemia risk: benzene as a model. [PDF]

, 1998
Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core   +3 more sources

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report

Онкогематология, 2022
Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which is usually manifested by hyperleukocytosis and massive splenomegaly. Chronic myeloid leukemia is rare in childhood and adolescence, it accounts for 2 to 3 % of all leukemias ...
T. Yu. Pavlova, T. T. Valiev
doaj   +1 more source